Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

Reality Check for AARP


This morning, AARP released yet another misleading report on prescription drug prices that ignores key facts about the marketplace for medicines. The report suffers from several notable flaws. Most glaringly, AARP underplays the value of the Medicare Part D program and ignores the stability in the program brought about by market competition: Average annual out of pocket spending on drugs for Medicare Part D beneficiaries has fallen in recent years, declining 16 percent between 2007 Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

BIO CEO & Investor Conference Closes with Record Breaking Partnering Numbers


The 18th Annual BIO CEO & Investor Conference, the largest investor conference focused on established and emerging publicly traded and select private biotech companies, took place this earlier this week in New York City at the Waldorf Astoria with more than 1,400 registrants, including over 600 registered investors. The event featured 9 educational program sessions, including business roundtables, therapeutic workshops and plenary sessions, 6 fireside chats with biopharma CEOs as well as a special guest, New York Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

#BIOCEO16 Session Recap: Regulatory Policy Outlook—PDUFA VI and You

CEO2013_115x75_Thumbnail copy

The second day of #BIOCEO16 kicked off this morning with a look ahead to PDUFA VI and potential ways to improve the drug development and approval process. Moderated by BIO Executive Vice President of Emerging Companies Cartier Esham, the panelists included: Elizabeth Krutoholow, Analyst, Bloomberg Intelligence Jonathan Leff, Partner, Deerfield Management; Chairman, Deerfield Institute Richard F. Pops, Chairman & Chief Executive Officer, Alkermes The challenges and opportunities presented by the growing amount of available “real Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

#BIOCEO16 Fireside Chat with Senator Chuck Schumer

CEO2013_115x75_Thumbnail copy

New York Senator Chuck Schumer joined attendees at the 2016 BIO CEO & Investor Conference this afternoon for a fireside chat, moderated by BIO Chairman Ron Cohen, to discuss current political and public policy issues facing the country and the biopharmaceutical industry. The Senator expressed optimism that progress can be made on a bipartisan basis in a number of areas that will be conducive to investment in medical innovation and the well-paying jobs that such Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: ,

Tomorrow: From Volume to Value: Designing a Patient-Centered Healthcare System (Webcast)


Tomorrow at the Newseum, The Hill will be hosting a live discussion about the transition from volume-based to value-based care. A live webcast will be available for the event, which begins at 8:30 am ET. Last week, Jim Robinson, President of Astellas Pharma US, shared his thoughts in a related op-ed at The Hill. Biopharmaceutical innovation is transforming what it means to be a patient battling some of our most difficult diseases, such as cancer, Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post